Aspira Women's Health Inc. Reports Board and Officer Changes

Ticker: AWHL · Form: 8-K · Filed: Jan 31, 2025 · CIK: 926617

Sentiment: neutral

Topics: management-change, board-of-directors, officer-departure

Related Tickers: AWH

TL;DR

Aspira Women's Health (AWH) board shake-up: new directors elected, some officers out.

AI Summary

Aspira Women's Health Inc. announced on January 28, 2025, a change in its board of directors. Specifically, the company reported the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for its officers.

Why It Matters

Changes in board composition and officer roles can signal shifts in company strategy, leadership, and governance, potentially impacting future performance and investor confidence.

Risk Assessment

Risk Level: medium — Board and officer changes can indicate internal instability or strategic realignments, which carry inherent risks.

Key Players & Entities

FAQ

Who are the specific officers that departed from Aspira Women's Health Inc.?

The filing indicates the departure of certain officers but does not name them specifically in the provided text.

Who are the newly elected directors to the Aspira Women's Health Inc. board?

The filing states that directors were elected but does not provide their names in the provided text.

What specific changes were made to the compensatory arrangements of the officers?

The filing mentions updates to compensatory arrangements but does not detail the specifics of these changes in the provided text.

What is the effective date of these board and officer changes?

The earliest event reported is January 28, 2025, which is the date of the changes.

Does this 8-K filing disclose any financial performance metrics?

No, this 8-K filing focuses on changes in directors and officers and compensatory arrangements, not financial performance.

Filing Stats: 740 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2025-01-31 06:15:25

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aspira Women's Health Inc. Date: January 31, 2025 By: /s/ Michael Buhle Michael Buhle, Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing